NHS Greater Glasgow and Clyde Investigating Favipiravir as Early Onset Treatment for Mild to Moderate COVID-19 in Scotland
Scotland
has kicked off a favipiravir-based study investigating the efficacy and safety of that antiviral drug targeting COVID-19 cases in Caledonia.
Organized by the Glasgow University with support from the Glasgow Clinical Research Facility,
thanks to financial infusion from the Chief Scientist Office of the Scottish Government,
Principal investigator Rob Jones, Director of the CRUK Clinical Trials Unit,
leads a team presently recruiting participants here to help contribute to the war against the coronavirus.
a favipiravir-based study
Can favipiravir, already approved for COVID-19 clinical care in Russia and several other countries,
help patients with early onset, mild to moderate COVID-19 cases in Scotland.
The Study
The NHS Greater Glasgow and Clyde and the University of Glasgow guide the study known here as the Glasgow Early Treatment Arm Favipiravir (GETAFIX) study.
Studying the impact of favipiravir, whether the antiviral can reduce the time it takes to recover, prominent local hospitals serve as trial sites.
These sites include three NHSGGC hospitals, including
Queen Elizabeth University Hospital, Glasgow Royal Infirmary and Royal Alexandra Hospital and a designated outpatient facility for treating patients out in the community.
Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial | Trials | Full Text
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04891-1